Cargando…
A new paradigm for classifying and treating HER2‐positive breast cancer
BACKGROUND: Because of the phenomenal success of treatment with monoclonal antibodies and antibody‐drug conjugates targeting human epidermal growth factor receptor 2 (HER2), most patients with early‐stage HER2‐positive breast cancer (HER2+ BC) and some with limited metastatic diseases have been cure...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432420/ https://www.ncbi.nlm.nih.gov/pubmed/37254964 http://dx.doi.org/10.1002/cnr2.1841 |